A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease
NCT ID: NCT01194362
Last Updated: 2022-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
105 participants
OBSERVATIONAL
2010-09-30
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Genetic Causes of Calcific Aortic Valve Disease
NCT04149600
Identification of Genetic Causes of Bicuspid Aortic Valve Disease
NCT01026571
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
NCT03440697
Identification of Genes Expressed in Atherosclerotic Plaque
NCT00353730
Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications
NCT00647088
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Early identification of those patients with BAV disease who are at risk for ascending aneurysm formation and its complications may allow early intervention to prevent rupture, dissection and emergent cardiac surgery in at risk patients. Conversely, identification of those patients with BAVs not at risk for aortic aneurysm formation would delineate which patients do not need close follow up of aortic size or prophylactic ascending aortic replacement at time of aortic valve replacement.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
45 specimens collected from BAV patients
No interventions assigned to this group
45 specimens collected from TAV patients
No interventions assigned to this group
15 specimens collected from CABG pts
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting with aortic stenosis and to undergo elective aortic valve replacement or repair with or without aortic aneurysm dilation repair
* Able to sign informed consent document
Exclusion Criteria
* Patients with predominant aortic regurgitation valve disease
* Patients with other known connective tissue disorders (such as Marfan's Syndrome, Ehlers-Danlos Syndrome)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Brinkman, MD
Role: PRINCIPAL_INVESTIGATOR
The Heart Hospital Baylor Plano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Heart Hospital Baylor Plano
Plano, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
010-161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.